We found that the clinical response of patients with high baseline levels of TNF (baseline-TNF) showed a significant improvement with higher doses of infliximab, whereas patients with low baseline-TNF did not have a better response even with higher doses of infliximab.
It is highly likely that patients whose tumours express low ATase activity would obtain a better response with O-alkylating agents than those with tumours expressing higher levels.
A better response and higher weight loss correlated with higher doses of medication.
To circumvent these molecular targets, vemurafenib, a highly selective inhibitor of BRAF V600E mutation, was developed and have shown clear clinical benefits including significantly better response and higher OS rates compared with commonly utilized standard chemotherapy agents [ 22].
Although there seems to be a trend (p = 0.051) towards better response in patients with higher NLR this trend was not statistically significant with an R Square of 0.028.
Similarly, a better response was associated with higher CL (P=0.023).
24 To demonstrate that high-dose daptomycin combined with fosfomycin achieves a better response than therapy with high-dose daptomycin alone, measured in terms of clinical success plus microbiological success (treatment success) at week 6 after end of therapy (test-of-cure visit, TOC).
Patients with high viral load at switch are at high risk of early failure and may deserve special strategies: to note that both clinical trials testing combinations with raltegravir [ 4, 5] showed a trend towards a better response in patients with high viral load using raltegravir than NRTI in combination with bPI.
High HER2 copy number (>12) appears to be associated with consistently better response compared with patients with intermediate HER2 copy numbers (6 12).
High TS and TP expression with low ERCC1 expression (0 2 vs 3) showed a significantly better response compared with other levels of expression (high TS and TP and low ERCC1 vs other levels of expression, RR 63.2 vs 36.8%, P=0.016; Table 3, Figures 2, 3 and 4).
